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ABSTRACT
Background: Depression and Health Related Quality of Life have been associated 
with prognosis in lung cancer. As the Distress Thermometer measures emotional 
problems and may share similarities with aspects of Health Related Quality of Life, 
we aimed to retrospectively assess the prognostic value of the Distress Thermometer 
in lung cancer patients treated with chemotherapy.
Methods: Patients with stage III lung cancer who were treated at the day-care 
oncology unit with chemotherapy containing carboplatin from 2009 to 2014 and 
in whom a Distress Thermometer was performed at the time of the first cycle of 
chemotherapy were included in this study.
Results: In total, one hundred and thirteen patients were included in the analysis. 
In the simple Cox regression analysis, overall survival did not significantly differ 
according to Distress Thermometer score. No significant differences in Distress 
Thermometer score according to stage, histology, (intended) treatment, age, sex, and 
comorbidity were observed. Also in a multivariable model the Distress Thermometer 
was not prognostic for overall survival, whereas sex and (intended) treatment was.
Conclusions: In this study no prognostic value of the Distress Thermometer could 
be established in patients with stage III lung cancer treated with carboplatin. Further 
research is warranted to address this issue.
INTRODUCTION
Distress reflects the spectrum of psychological 
problems (i.e. cognitive, emotional, social, and spiritual) 
associated with a diagnosis and treatment of cancer and 
can be measured by the Distress Thermometer (DT) [1-3]. 
In general, the DT is completed together with a problem 
list. The clinical application of the DT has been extensively 
investigated in patients with different forms and stages of 
malignancies, demonstrating acceptable to good accuracy in 
detecting distress [4-7] as well as change in distress [8]. One 
study in patients diagnosed with breast cancer demonstrated 
that moderate to severe distress was related to a significant 
decrease in Health Related Quality of Life (HRQoL) and that 
for the Quality of Life (QoL) scales for which a minimally 
important difference has been established this decrease 
ranged from two to three and a half times the established 
minimally important difference [9]. According to the results 
of this study, the DT could address aspects of distress beyond 
psychological problems and is therefore linked to HRQoL. 
Furthermore, the resemblance of items of the problem list 
with items of HRQoL questionnaires (e.g. the European 
Organization for Research and Treatment of cancer Quality 
of Life Questionnaire-Core 30 (EORTC QLQ-C30)), and the 
good to moderately strong relation of the problem list with the 
DT [6] support an association with HRQoL. To date, multiple 
studies have evaluated HRQoL as a predictor of survival in 
lung cancer patients [10-16]. Overall/global HRQoL is often 
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observed to be a prognostic factor in these studies [10, 13-
16]. Considering that depression has been associated with 
a decreased survival in patients with lung cancer [17, 18] 
and the considerable overlap between the problem list and 
HRQoL, the DT may be utilised as a fast, efficient, and 
promising tool to provide prognostic information similar 
as overall/global HRQoL does. Especially in lung cancer 
patients with a limited prognosis and who are at risk for 
cancer and treatment related adverse events and thus a decline 
in HRQoL this may be of importance. As the relation of the 
DT with survival has not been investigated before in lung 
cancer, we hypothesized that the DT is a predictor for overall 




Patients diagnosed with lung cancer treated at 
the day-care oncology unit of a large teaching hospital 
(Amphia Hospital, Breda, The Netherlands) specialized 
in lung cancer care from August 2009 until August 2014 
were retrospectively enrolled in our study if they met the 
following criteria: they were aged 18 years or older, were 
diagnosed with stage III non-small cell lung carcinoma 
(NSCLC) or stage III small cell lung carcinoma (SCLC) 
according to TNM 7th edition [19], were treated with first line 
chemotherapeutic regiments containing carboplatin, had a 
level of functioning which indicated that completion of the 
DT could be beneficial to optimize care, and had completed 
the DT at least at the time of the first cycle of treatment. We 
limited our inclusion to patients treated with carboplatin as the 
DT was more consistently performed in the day-care clinic of 
our department than at the clinical oncology unit. To optimize 
homogeneity of the patient sample only patients with stage III 
disease were analyzed as this was the largest population in 
our series. Patients with cisplatin treatment were not included 
as they require hospitalization. If no information on clinical 
treatment or survival was available, patients were excluded. 
As the included patients received standard care and were not 
exposed to additional interventions this study did not fall 
under the Medical Research Involving Human Subjects Act 
(WMO). In addition, informed consent of each patient was 
not required as the all data was handled to Dutch privacy law 
Therefore, permission of a medical ethics committee was not 
necessary.
The Distress Thermometer
The DT is a visual analogue scale originally 
developed to describe the level of distress patients 
experience. Its scale ranges from 0 (no distress) to 10 
(extreme distress) [1]. The DT is completed together with 
the problem list by patients at the time of the first, third, 
and fourth cycle of chemotherapy at our department. The 
Dutch version of the problem list comprises 47 items. 
It addresses practical, social, emotional, spiritual, and 
physical problems. The psychometric properties of the 
DT combined with the Dutch problem list have been 
investigated by Tuinman et al. [6]. They observed a 
good internal consistency, except for practical problems 
(α= 0.60) and spiritual problems (α= 0.64). In addition, 
a strong correlation between the DT and emotional 
problems (r= 0.61), physical problems (r= 0.64), and the 
total problem list (r= 0.68) was found. Tuinman et al. 
reported a sensitivity of 0.85 and a specificity of 0.69 of 
the DT at a cut-off value of five after performing receiver 
operator characteristics analysis with a Hospital Anxiety 
Depression Scale score of ≥ 15 as a gold standard [6].
Additional information
Sociodemographic information (age, gender), 
comorbidity, histological tumor type (adenocarcinoma, 
squamous cell carcinoma, NSCLC otherwise not 
differentiated or adenocarcinoma in situ, and SCLC, 
cancer stage according to TNM 7th edition (IIIA and IIIB; 
patients originally staged according to TNM 6th edition 
were restaged using TNM 7th edition) [19], treatment 
(chemotherapy, surgery in combination with (neo)
adjuvant chemotherapy or chemotherapy in combination 
with radiotherapy (i.e. concurrent or sequential), and OS 
was retrieved from the electronic patient information 
system and the cancer registration of the Netherlands 
Comprehensive Cancer Organisation.
Statistical analysis
The Mann-Whitney U test and one-way ANOVA 
were used to compare DT scores obtained at the time of 
the first cycle of chemotherapy.
Patient’s OS was defined as the time between date 
of histological diagnosis and date of death from any cause 
or date of last contact/last known to be alive. Patients who 
were still alive at the time of analysis were censored at 31 
December 2014.
Survival probabilities were estimated and expressed 
by Kaplan-Meier curves. Curves were compared with 
the log rank test. Univariable Cox proportional hazards 
models were used to evaluate the DT at the first cycle 
of chemotherapy to be a predictor for OS. In addition, 
univariable Cox proportional hazards models were built 
to evaluate the individual significance of the pretreatment 
covariates as a predictor of OS. Covariates (i.e., age, 
gender, comorbidity, histology, Charlson Comorbidity 
Index and (intended) treatment) were chosen as based on 
previous studies.
The DT score was then entered in a multivariable 
Cox proportional hazards model with the remaining 
determinants after univariable analyses. Models were used 
in which the DT was analyzed as a continuous variable, 
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and as a dichotomous variable. Dichotomous variables 
were created by categorizing patients into two groups 
based on the DT cut-off value of five as proposed by 
Tuinman et al. [6].
P-values of p≤ 0.05 were regarded as significant. 
Data were analyzed with the use of IBM SPSS Statistics 
for Windows version 21.0.
RESULTS
Patients and results of the DT
Table 1 describes the included patients. Of the 495 
identified patients treated with carboplatin chemotherapy, 
281 were discarded from the analyses since the DT was 








P DT <5 DT ≥5
Age, years
 Mean (SD) 63.3 (8.7)
 Min, max 37, 79
Sex a
 Male 64 (56.6) 3.3 (2.7) 3.0 (0.0-9.0) 0.91 43 (38.1) 21 (18.6)





 Adenocarcinoma 52 (46.0) 3.3 (2.5) 3.0 (0.0-9.0) 0.18 34 (30.1) 18 (15.9)
 Squamous cell carcinoma

















 Min, max 0, 5
 0-1 a 98 (86.7) 3.2 (2.4) 3.0 (0.0-9.0) 0.42 67 (59.3) 31 (27.4)
 >2 15 (13.3) 4.0 (3.3) 5.0 (0.0-9.0) 7 (6.2) 8 (7.1)
Treatment b
 Chemotherapy 9 (8.0) 4.2 (2.7) 5.0 (0.0-8.0) 0.34 4 (3.5) 5 (4.4)
  Surgery and (neo) adjuvant 
chemotherapy 14 (12.4) 3.9 (2.7) 4.0 (0.0-9.0) 9 (8.0) 5 (4.4)
  Chemotherapy and sequential/
concurrent Radiotherapy 90 (79.6) 3.1 (2.5) 3.0 (0.0-9.0) 61 (54.0) 29 (25.7)
Values are given in numbers (percentages) and means unless stated otherwise.
a P-values calculated with the Mann-Whitney U test.
b P-values calculated with one-way ANOVA. Abbreviations: n, number of patients; SD, standard deviation; DT, distress 
thermometer score at first cycle of chemotherapy; NSCLC, non-small cell lung carcinoma; SCLC, small cell lung 
carcinoma, CCI, Charlson Comorbidity Index.
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not completed at the first cycle of chemotherapy. Of the 
remaining 214 patients, 113 patients were diagnosed 
with stage III disease. The age of these patients ranged 
from 37 to 79 years, with a mean of 63.3 (SD 8.7). 
Forty-six percent of the patients were diagnosed with 
adenocarcinoma. The majority of the patients received a 
combination of chemotherapy and radiotherapy. Thirty-
nine patients (34.5%) demonstrated DT scores higher than 
the cut-off score of ≥ 5. No significant differences were 
observed between distributions of scores or mean scores 
of the DT for different patient characteristics.
Survival estimates and cox proportional hazards 
models
Patients with a DT score < 5.0 did not differ 
to patients with a score of ≥ 5.0 with regard to age, 
sex, histology, comorbidity, and (intended) treatment. 
Figure 1 shows the Kaplan-Meier curves of the patients 
dichotomized by a cut-off score ≥ 5.0. No significant 
differences were observed (p= 0.98). Age and (intended) 
treatment independently predicted OS (Table 2). The DT 
score at the first cycle of chemotherapy as a continuous 
variable was in the univariable analysis not prognostic 
for OS. Utilizing a dichotomized DT (cut-off ≥ 5) in 
the univariable analysis revealed similar results. The 
multivariable model with age and (intended) treatment as 
variables demonstrated only (intended) treatment to be a 
significant factor for decreased OS.
DISCUSSION
To the best of our knowledge, the present study 
is the first in which the association between distress 
as measured by the DT with OS in cancer is studied. 
Although the DT and its problem list have some common 
grounds with generic HRQoL instruments, we were not 
able to identify it as a prognostic factor for OS in lung 
cancer.
It is possible that our negative results are explained 
by the inability of the DT to measure all aspects of 
HRQoL. Validity of the DT has been demonstrated by 
comparison with questionnaires investigating aspects 
related to cognitive and emotional functioning [20], 
but not with generic HRQoL questionnaires. Tuinman 
et al. demonstrated that the DT had a high correlation 
with the physical (r= 0.64) domain and was moderately 
associated with the practical (r= 0.39) and family/social 
domain (r= 0.31) of the problem list [6]. Generic HRQoL 
questionnaires, such as the EORTC QLQ-C30, address 
similar aspects of a patient’s well-being (e.g. physical 
functioning/symptoms, social functioning). It would be 
interesting to explore whether the validity of the DT and 
its problem list can be established by comparing them with 
such instruments [6]. Similar to the study of Tuinman et al. 
we had to exclude identified large number of patients [6]. 
This may be explained by several reasons. First, patients 
may refuse to complete the DT and the problem list due to 
the length of the instrument (47 problems). Moreover, as 
Figure 1: Overall survival based on Distress Thermometer (DT) score at first cycle of chemotherapy.
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the items of the problem list can only be answered by YES 
or NO, patients may not recognize their situation in these 
options, or may consider some of the items as irrelevant. 
Secondly health care personnel may not have provided the 
DT to patients on a regularly basis as the score of the DT 
would not likely result in adjustment of care. This holds 
true for patients considered not to experience any distress 
but also in patients experiencing high levels of distress in 
whom already extra measures are taken.
Given the previous considerations, the included 
patients are likely to represent a population in which 
patients with the best and those with the worst clinical 
status were not selected. It is likely this selection bias 
contributed to the negative results of this study. For future 
studies, it might be of interest to include a broader patient 
population and to investigate whether completion of 
patient outcome measures (such as the DT) is influenced 
by a reduced HRQoL at the start of treatment or due to 
treatment related side-effects.
We found the mean DT score in our patients to be 
comparable with other studies in lung cancer [3, 21] but 
lower as seen in patients with cancer from other sites 
[6, 7]. This finding is in contrast with the knowledge 
that many lung cancer patients have a bad prognosis and 
considerable diagnosis and treatment related stress. An 
explanation for this observation could be the in general 
low socio-economic status of lung cancer patients which 
could prevent them from adequately expressing their 
distress. Moreover, distress may also be influenced by age. 
Recently, it has been demonstrated that an increased age 
Table 2: Results of the univariable and multivariablea analyses for OS
Univariable analyses Multivariable analysis
Covariates HR 95% CI HR 95% CI
DT 1.02 0.91-1.14
DT
 <5 0.99 0.56-1.76
 ≥5b
Age 1.04 1.00-1.07 1.03 1.00-1.07
Sex
 Male
 Femaleb 0.71 0.41-1.22
Histology
 Adenocarcinomab
 Squamous cell carcinoma 1.72 0.95-3.13
 NSCLC otherwise not specified, 
adenomatous hyperplasia 1.33 0.31-5.71
 SCLC 1.01 0.43-2.39
CCI
 0-1 0.98 0.44-2.18
 > 2b
Treatment
 Surgery and (neo)adjuvant chemotherapyb
 Chemotherapy 1.45 0.57-3.71 1.43 0.56-3.66
  Chemotherapy and sequential/concurrent 
radiotherapy 6.87 2.16-21.85 6.34 1.99-20.19
aAll variables entered together in one block.
bReference group.
Abbreviations: OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; DT, distress thermometer score 
at first cycle of chemotherapy as a continuous variable; NSCLC, non-small cell lung carcinoma; SCLC, small cell lung 
carcinoma, CCI, Charlson Comorbidity Index.
Oncotarget36748www.impactjournals.com/oncotarget
is related to the experience of decreased distress in cancer 
[22]. As lung cancer patients, in general, have a higher 
age at diagnosis, this may also explain the relatively 
low mean DT score. Thirdly, a considerable part of lung 
cancer patients have severe comorbidity (e.g. cardiac and 
pulmonary disease) [23] so that they are familiar with a 
certain amount of distress.
Given the potential relationship of the DT with 
global/overall HRQoL, we used only the DT without the 
problem list to perform the calculations in this report. 
However, the negative results of our study should not 
prevent further prospective research of the DT and the 
problem list beyond their intended use. The role of the 
DT and the problem list should be more extensively 
evaluated in studies investigating patient reported outcome 
measures to determine its concurrent validity with 
generic HRQoL questionnaires, to evaluate its validity 
and reliability in lung cancer and to assess its prognostic 
relevance. Such studies may offer opportunities to enhance 
the implementation of the DT and problem list in daily 
practice, to recognize patients who are prone to a negative 
change in HRQoL during treatment and to identify even 
those patients at risk for a poorer prognosis.
In conclusion, the DT was not found to be prognostic 
in a cohort of patients with stage III disease treated with 
Carboplatin. Further prospective investigations are 
warranted incorporating a large patient cohort with a 
broader treatment regimen.
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